Researchers at the University of Michigan reviewed published and unpublished trials of serotonin receptor inhibitors (SRI) for the treatment of autism spectrum disorders (ASD). The published literature showed a significant benefit of SRIs for ASD behaviors, but the researchers found significant evidence of publication bias in all analyses. When analyses were corrected for publication bias, the researchers found no significant benefit of SRIs for the treatment of ASD. Results will be published in Pediatrics.
Related Item:
U.S. News
